D. E. Shaw & Co. Inc. Has $1.46 Million Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

D. E. Shaw & Co. Inc. decreased its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 45.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 304,146 shares of the biopharmaceutical company's stock after selling 255,652 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.52% of Vanda Pharmaceuticals worth $1,457,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of VNDA. XTX Topco Ltd acquired a new stake in Vanda Pharmaceuticals during the fourth quarter valued at approximately $69,000. Zacks Investment Management bought a new position in shares of Vanda Pharmaceuticals in the 4th quarter worth about $74,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Vanda Pharmaceuticals by 17.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company's stock valued at $107,000 after buying an additional 3,370 shares during the period. Tudor Investment Corp ET AL grew its position in shares of Vanda Pharmaceuticals by 59.5% during the 4th quarter. Tudor Investment Corp ET AL now owns 24,618 shares of the biopharmaceutical company's stock valued at $118,000 after buying an additional 9,180 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in Vanda Pharmaceuticals by 26.8% during the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock worth $124,000 after acquiring an additional 5,459 shares during the period. Hedge funds and other institutional investors own 88.14% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Wall Street Zen assumed coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a "hold" rating for the company. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday, May 7th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 14th.

Insiders Place Their Bets

In related news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was acquired at an average cost of $5.02 per share, with a total value of $50,200.00. Following the purchase, the chief executive officer now directly owns 2,285,731 shares in the company, valued at $11,474,369.62. The trade was a 0.44% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders have acquired 50,000 shares of company stock worth $226,200. 10.00% of the stock is owned by corporate insiders.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA stock traded up $0.04 during midday trading on Wednesday, reaching $4.37. 17,041 shares of the company were exchanged, compared to its average volume of 712,619. The company's 50 day moving average price is $4.34 and its two-hundred day moving average price is $4.60. The company has a market cap of $257.25 million, a P/E ratio of -13.71 and a beta of 0.69. Vanda Pharmaceuticals Inc. has a 12 month low of $3.81 and a 12 month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.05. The firm had revenue of $50.04 million during the quarter, compared to analyst estimates of $45.13 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. As a group, sell-side analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.